



New Advances in the Treatment of Resectable Non-small Cell Lung Cancer

Guest Editors:

Dr. Francesco Facciolo

Thoracic Surgery Department,
IRCCS Regina Elena National
Cancer Institute, 00144 Rome,
Italy

Dr. Luca Bertolaccini

Department of Thoracic Surgery -
IEO, European Institute of
Oncology IRCCS, Milan, IT, Italy

Dr. Federico Cappuzzo

Medical Oncology, IRCCS Regina
Elena National Cancer Institute,
00144 Rome, Italy

Deadline for manuscript
submissions:

closed (15 September 2023)

Message from the Guest Editors

Despite the evolution in non-small cell lung cancer treatment, the overall prognosis is still poor. In this context, lobectomy and radical lymphadenectomy remain the cornerstone of surgical treatment of resectable NSCLC. One of the most important prognostic factors remains the presence of lymph node involvement, particularly the presence of mediastinal nodal involvement. Furthermore, correct intraoperative staging is mandatory to reach an actual pathological status of the disease. The recent approval of Osimertinib for resected EGFR-mutated NSCLC in an adjuvant setting has led to the hypothesis that other targeted therapies used in metastatic patients can also lead to improved early-stage outcomes of NSCLC. Indeed, in addition to surgical treatment, some target therapies are being tested in adjuvant settings with promising outcomes. For this Special Issue, we welcome reviews and original research focusing on recent advancements in the preoperative staging, the surgical resection of NSCLC, the role of the new medications approved as adjuvant and neoadjuvant therapies, economic evaluation, and cost-effectiveness.

